Free Trial
OTCMKTS:BIOQ

Bioqual Q1 2026 Earnings Results & Report

Bioqual logo
$31.00 0.00 (0.00%)
As of 11/12/2026

Bioqual reported Q1 2026 earnings on October 21, 2025. The company reported EPS of -$0.28, while revenue was $9.85 million.

Earnings Announcement Details

Quarter
Q1 2026
Report Date

Bioqual EPS Results

Actual EPS
-$0.28
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Bioqual Revenue Results

Actual Revenue
$9.85 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Bioqual Q1 2026 Earnings FAQ

Bioqual (OTCMKTS:BIOQ) reported earnings of -$0.28 per share for Q1 2026. The report was announced on Tuesday, October 21, 2025.

Bioqual reported revenue of $9.85 million for Q1 2026.

Bioqual Earnings Headlines

Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
BIOQUAL Presents Financial Results for Fiscal Year 2026
See More Bioqual Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bioqual? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bioqual and other key companies, straight to your email.

About Bioqual

Bioqual (OTCMKTS:BIOQ), Inc. is a biomedical research and contract research organization based in the United States. The company provides preclinical research services to pharmaceutical and biotechnology companies, government agencies, and other organizations developing medical treatments, vaccines, and diagnostics.

Its activities include animal-model research, pharmacology, toxicology, infectious-disease studies, and vaccine and therapeutic efficacy testing. Bioqual has experience conducting research involving nonhuman primates and other laboratory animals, supporting the evaluation of potential products before they advance to human clinical trials.

The company’s services are designed to help clients assess safety, effectiveness, and biological responses across a range of medical and public-health applications. Publicly available information about Bioqual’s current leadership, geographic reach, and additional operating details is limited.

View Bioqual Profile